Skip to search formSkip to main contentSkip to account menu

BMS247550

Known as: BMS 247550, BMS-247550, Epothilone-B BMS 247550 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Epothilonesixabepilone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS).
Ixabepilone (BMS-247550, Ixempra is a semi-synthetic analog of the natural product epothilone B and marketed for its use in the… 
2008
2008
Synergistic Antitumor Activity of Ixabepilone (BMS-247550) Plus Bevacizumab in Multiple In vivo Tumor Models
Purpose: Angiogenesis is a critical step in the establishment, growth, and metastasis of solid tumors, and combination of… 
Highly Cited
2007
Highly Cited
2007
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
PURPOSE To establish the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, pharmacokinetics, and… 
2005
2005
Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium.
PURPOSE Epothilones are a new class of nontaxane tubulin polymerization agents that have activity in taxane-resistant tumors… 
2005
2005
A translational study of ixabepilone (BMS-247550) in renal cell cancer (RCC): Assessment of its activity and demonstration of target engagement in tumor cells
4541 Background: Agents targeting microtubules (MTs) are very effective anticancer drugs. Ixabepilone is a novel MT-stabilizing… 
2005
2005
Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer (BC): Preliminary efficacy and safety data
586 Background: Previous studies have confirmed the activity of ixabepilone (BMS-247550, a semi-synthetic analog of epothilone… 
2005
2005
The epothilone dilemma.
Because of their potent antitumor activity, drugs targeting microtubules are among the most commonly prescribed anticancer agents… 
2004
2004
Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (S0111)
4510 Background: The epothilones are a new class of non-taxane tubulin polymerizing agents with activity both in taxane-sensitive… 
2004
2004
A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) in patients with advanced pancreas cancer: A Southwest Oncology Group Study.
4012 Background: Advanced metastatic pancreatic cancer has a poor prognosis and short median survival with standard therapy. BMS… 
Highly Cited
2002
Highly Cited
2002
Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study.
The primary aims of this study were to evaluate the timecourse and dose response of microtubule bundle formationin peripheral… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)